This preclinical study evaluated the efficacy of convection-enhanced delivery (CED) of bevacizumab, alone or combined with irinotecan, in murine models bearing intracranial gliomas (U87 and U251 cell lines). CED-treated mice demonstrated a 30% longer survival compared to those receiving intravenous (IV) bevacizumab. The combination of CED bevacizumab and intraperitoneal irinotecan
